Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Venlafaxina

Efexor, Zarelis, Faxine e altri

Bibliografia - Quali fonti bibliografiche per Venlafaxina?

1. Abdelmawla A.H. et al., Br. J. Clin. Pharmacol., 1999, 48, 345.

2. Akkaya C. et al., Hum. Psychopharmacol., 2006, 21 (5), 337.

3. Altamura A.C. et al., Int. Clin. Psychopharmacol., 1999, 14 (4), 239.

4. Can. J. Psychiatry, 2003, 48 (2), letter.

5. Combes A. et al., Ann. Int. Med., 2001, 134, 166.

6. Cunningham L.A.,et al., J. Clin. Psychopharmacol., 1994, 14, 99.

7. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.

8. Davidson J.R. et al., J. Clin. Psychiatry, 1999, 60 (8), 528.

9. De Abajo F.J. et al., BMJ, 1999, 319, 1106.

10. Drent M. et al., Am. J. Respir. Crit. Care Med., 2003, 167, 958, (abstract).

11. Einarson A. et al., Am. J. Psychiatry, 2001, 158, 1728.

12. Evans M.L. et al., Obstet. Gynecol., 2005, 105, 161.

13. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.

14. Fabre L.F., Putman III H.P., Curr. Ther. Res., 1987, 42, 901.

15. Ferguson J. et al., Neuropsychopharmacology, 1994, 10 (2), 117.

16. Fisher A., Davis M., Ann. Pharmacother., 2002, 36, 67.

17. Fleisch M.C. et al., Eur. Respir. J., 2000, 15, 205.

18. Garcia Muret M.P. et al., 58th Ann. Meeting Am. Acc. Dermatol., 2000, 10 marzo.

19. Gelemberg A.J. et al., JAMA, 2000, 283 (23), 3082.

20. Gründer G. et al., Pharmacopsych., 1993, 26, 155.

21. Hannan N. et al., J. Psychopharmacol., 21 (2), 2007, 161.

22. Kaplan E.M. et al., Clin. Ther., 2002, 24, 1194.

23. Kelsey J.E. et al., Psychopharmacol. Bull., 1995, 31 (4), 767.

24. Lancet, 2009, 373, 746.

25. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.

26. Lee Y. et al., Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 1139.

27. Loprinzi C.L. et al., Lancet, 2000, 356, 2059.

28. Loprinzi C.L. et al., J. Clin. Oncol., 2006, 24 (9), 1409.

29. Mason P.J. et al., Medicine, 2000, 79, 201.

30. Markovitz P.J., Wagner S.C., Psychopharmacol. Bull., 1995, 31 (4), 773.

31. McCue R.E., Joseph M., Am. J. Psychiatry, 2001, 158, 2088.

32. Meijer W.E. et al., Arch. Intern. Med., 2004, 164, 2367.

33. Mills K.C., Critical Care Clinics, 1997, 13, 763.

34. Montgomery S.A. et al., J. Psychiatr. Res., 2002, 36 (4), 209.

35. Montgomery S.A. et al., J. Clin. Psychiatry, 2006, 67 (5), 771.

36. Moses-Kolko E.L. et al., JAMA, 2005, 293, 2372.

37. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.

38. Muth E.A. et al., Biochem. Pharmacol., 1986, 35, 4493.

39. Muth E.A. et al., Drug Dev. Res., 1991, 23, 191.

40. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.

41. Papp et al. Psychopharmacol. Bull., 1998, 34 (2), 207.

42. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.

43. Perry N, Postgraduate Medical Journal, 2000, 76, 254.

44. Prescr. Int. 1998, 7 (36), 112.

45. Prescr. Int., 2004, 13, 57.

46. Preskorn S.H. et al., Eur. J. Psychiat., 1997, 12 (Suppl. 4), 285S.

47. Prior F.H. et al., Med. J. Austr., 2002, 176, 240.

48. Saletu B. et al., Br. J. Clin. Pharm., 1992, 33, 589.

49. Schweizer E. et al., J. Clin. Psychopharmacol., 1991, 11, 233.

50. Silverstone P.H., Ravindra A., J. Clin. Psychiatry, 1999, 60 (1), 22.

51. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.

52. Troy S.M. et al., J. Clin. Pharmacol., 1995, 35 (4), 410.

53. van Walraven C. et al., BMJ, 2001, 323, 655.

54. Vanokoski, Sommarberg L., TABU, 2004, 6, 53.

55. Whyte I.M. et al., Quarterly J. Med., 2003, 96, 369.